Bluebird’s Eggimann joins Tessera team
Plus new board appointments at GSK and Alnylam, and updates from Zealand, Pharus and more
Flagship Pioneering-backed Tessera Therapeutics Inc. hired Anne-Virginie Eggimann as chief regulatory officer to lead U.S. and global regulatory science and program and portfolio management for Tessera’s gene editing development programs. The move for Eggimann comes just days after the first U.S. regulatory approval for bluebird bio Inc. (NASDAQ:BLUE), where she was chief regulatory officer.
Eggimann joins a team at Tessera that includes CEO Michael Severino, who was vice chairman and president of AbbVie Inc. (NYSE:ABBV), and President and CFO Howard Liang, who was CFO and Chief Strategy Officer at BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235). Tessera is developing a suite of gene editing tools based on mobile genetic elements that have the potential to create a broader range of genomic alterations than CRISPR, and closed a series C round with roughly $300 million in April. ...